What are the targeted drugs for gastric adenocarcinoma?

Share This Post

Gastric adenocarcinoma is also a relatively common type of cancer, and its incidence is relatively high in China. There are many ways to treat gastric adenocarcinoma. The most common method is surgical treatment. Especially the patients can be found in the early stage. The effect of surgical treatment is very good. For patients with advanced stage, radiotherapy and chemotherapy are often needed. Of course, targeted drugs can also be used for treatment. Let’s take a look at the targeted drugs for gastric adenocarcinoma.


Gastric cancer targeting drugs

The targeted drug ramucirumab is an antibody drug; in a phase 3 randomized controlled clinical trial, patients with advanced gastric cancer were treated with ramuciruma or placebo; patients in the ramuciruma group had longer progression-free survival than patients in the placebo group.

The selective activity of the drug allows patients receiving the drug to generally have mild toxic side effects, but the prevalence of hypertension in the ramuciruma group is slightly higher than that in the placebo group.

What are the targeted drugs for gastric adenocarcinoma?

There are currently two domestically approved adenocarcinoma targeted drugs, one is trastuzumab and the other is apatinib. These two kinds of targeted drugs have their own characteristics. Trastuzumab treatment has certain indications, and there is a specific type of tumor that is often referred to as HER-2 positive tumor. HER-2 positive, there are now two evaluation methods, one is to detect whether it is (+++) or immunohistochemical test (++) by immunohistochemistry, and use the FISH method to verify that it is positive, this We believe that treatment with trastuzumab is possible. Another targeted drug is apatinib. So far, we have only used it to treat or cure patients with advanced gastric cancer. After conventional two-line chemotherapy, we can consider apatinib for palliative treatment at the third line.

For example, first-line treatment with cisplatin and gatigio or second-line treatment with paclitaxel. Some other targeted drugs, such as those for the treatment of lung cancer and bowel cancer, have actually done a lot of research on gastric cancer, including bevacizumab and cetuximab, but they are very regrettable in the field of treatment of gastric adenocarcinoma Without success, they have not been able to prove how effective they are in treating gastric adenocarcinoma. To sum up, there are currently two targeted drugs for gastric adenocarcinoma, one is trastuzumab and the other is apatinib. They have different indications, and their usage is not the same, but ultimately they must be selected according to the specific situation of the patient.

Gastric cancer targeting drugs price

Gastric cancer can now be treated by targeted drugs, but the specific price has a certain relationship with the choice of drugs. If it is a domestic drug, the price is relatively lower, but if it is an imported drug, the relative price is higher. , And the price range of domestic and imported drugs is still very large. In the process of treating cancer, we must also pay attention to active cooperation, and we must not delay the treatment time.

The above briefly understands what are the targeted drugs for gastric adenocarcinoma. At present, there are two kinds of targeted drugs approved for the treatment of gastric adenocarcinoma in China, one is apatinib and the other is trastuzumab. The characteristics of these two targeted drugs are different, such as trastuzumab Monoclonal antibody, it has certain indications and certain pertinence. There are also certain differences in price.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy